Compare Repligen Corporation Common Stock (RGEN) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Transocean Ltd — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Transocean Ltd trades at $5.61 (market cap $6.31B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Transocean Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Transocean Ltd for 18 Days on average.
| RGEN | RIG | |
|---|---|---|
Market Cap | $11.14B | $6.31B |
Volume | 1,259,263 | 37,551,905 |
Sector | Health | Energy |
52-Week High | $194.57 | $7.58 |
52-Week Low | $102.87 | $3.23 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $11.02B | $10.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Transocean (RIG) trades at $5.65, up 0.89% today, with a bullish technical signal from moving averages. The company shows mixed fundamentals with strong revenue growth to $4.1B in 2026 but persistent net losses. Recent contract wins including an $80M Equatorial Guinea deal and DOJ approval for the $5.8B Valaris acquisition provide positive catalysts. Cash flow improvement is notable with operating cash flow reaching $995M in 2026.
RIG presents a speculative opportunity driven by offshore cycle strength and deleveraging potential, but high debt levels and negative profitability pose significant risks. Analyst consensus is divided with 39% buy ratings, reflecting optimism about contract backlog versus concerns about execution and financial leverage. The stock's upside depends on successful debt reduction and sustained offshore drilling demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
